TABLE 2.
Drug (dose [mg/kg]) | Result for lungs (blood) at postdosing time (h)b:
|
|||
---|---|---|---|---|
1 | 3 | 6 | 9 | |
None (control) | 6.1 ± 0.3c (1/3) | 5.4 ± 0.6c (2/3) | 6.1 ± 0.3c (2/3) | 6.2 ± 0.2c (2/3) |
Trovafloxacin (25) | 4.6 ± 0.2 (0/3) | 4.1 ± 0.5 (0/3) | 3.3 ± 0.2 (0/3) | 2.8 ± 0.3 (0/3) |
Ciprofloxacin (100) | 4.7 ± 0.2 (0/3) | 3.8 ± 0.5 (0/3) | 3.1 ± 0.5 (0/3) | 3.5 ± 0.5 (0/3) |
Sparfloxacin (50) | 4.9 ± 0.1 (0/3) | 3.7 ± 0.2 (0/3) | 3.8 ± 0.2 (0/3) | 3.0 ± 0.9 (0/3) |
Temafloxacin (100) | 4.4 ± 0.2 (0/3) | 3.0 ± 0.3 (0/3) | 1.7 ± 0.5 (0/3) | 1.3 ± 1.4d (0/3) |
Single s.c. doses were given 3 h after a bacterial challenge.
Values are means (log10 CFU per milliliter of whole lung homogenate) ± the standard deviation (n = 3). The detection limit was 1 log10 CFU/ml. The number of animals with positive blood cultures and the total number of animals are in parentheses.
Greater than all quinolone-treated groups (P < 0.001).
Lower than the value for ciprofloxacin (P < 0.05).